Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University

Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. AGNPF has signed an investigator-initiated clinical trial agreement with Yale University -a recurring type of alliance within the psychedelics space- for the study of multiple intravenous (IV) doses of DMT for the treatment of depression.

The novel trial will be led by experienced DMT researcher Dr. Deepak Cyril D’Souza, professor of psychiatry and director of the schizophrenia neuropharmacology research group at Yale's school of medicine. 

“After careful consideration, we chose to support Dr. D’Souza’s clinical DMT study and work with Yale University,” said Algernon’s CEO, Christopher J. Moreau.  

“A rising tide lifts all boats, and we feel a corporate responsibility as well to improve global awareness and support psychedelic medicine research when possible."  

Dr. D’Souza said the trial will enhance current understanding.

“The study may enhance our current understanding of the dosing regimen in the subjective effects induced by DMT.”

The clinical study will test the effect of Algernon’s proprietary cGMP (current Good Manufacturing Practices) DMT by comparing different dosages and constant infusion dosing regimens of the tryptamine drug in healthy control participants and individuals with depression. 

If results are positive, the company will own the IP rights of the clinical use of DMT as well as the possibility to negotiate licenses corresponding to this technology. 

Although treatment of psychiatric disorders with DMT is not Algernon’s current focus; the company holds patents pending on novel forms of DMT that could potentially be used across a broad range of diseases, including an ongoing DMT for stroke research programs, which will potentially be benefited from the present trial.

Photo courtesy of CDC on Pexels and Jynto on Wikimedia Commons.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsMarketsdepressionDMT Clinical TrialYale University
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!